Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review.

ABSTRACT:

Background

Gallbladder carcinoma (GBC) is a highly aggressive malignancy with limited treatment options and poor prognosis, particularly in advanced stages. Traditional chemotherapy often yields modest outcomes and can be poorly tolerated.

Materials and methods

We report a case of a 59-year-old woman with stage IVA GBC who was unable to tolerate first-line gemcitabine and cisplatin due to severe adverse effects. Next-generation sequencing revealed a moderate tumor mutation burden and microsatellite-stable status. Based on a multidisciplinary team assessment, she received camrelizumab (PD-1 inhibitor) plus apatinib (VEGFR2 inhibitor).

Results

After 11 cycles, imaging demonstrated significant tumor regression and reduced invasion, enabling successful radical resection.

SUBMITTER: Chen Z 

PROVIDER: S-EPMC12510835 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature